Amphix Bio, Inc.
Last verified 2026-05-05. JSON
| Total raised | $10.3M |
|---|---|
| Latest round | Funding round, $10.3M, 2025-12-19 |
| Founded | 2021 |
| Headquarters | CHICAGO, IL |
| Industry | bio |
| Stage | unknown |
| Website | amphixbio.com |
Amphix Bio develops supramolecular peptide therapeutics that form synthetic nanostructure scaffolds to drive regeneration after CNS injury, neuro-inflammatory disease and musculoskeletal damage. It serves patients with acute spinal cord injury, degenerative disc disease and similar high-need indications. Northwestern-derived cell-free peptide chemistry ships as defined synthetic drugs, sidestepping cell-therapy manufacturing complexity.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-12-19 | Funding round | $10.3M | undisclosed |
Detected tech stack
Google Cloud CDN, Sentry, Vercel Speed Insights, WebsiteBuilder, Wix, Google Cloud, React, lodash .
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $10.3M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $10.3M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | amphixbio.com, read 2026-05-05 |
| Description | self-reported | amphixbio.com, read 2026-05-05 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $10.3M, 2025-12-19 → Funding round, $10.3M, 2025-12-19, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $10.3M, 2025-12-19 → Funding round, $10.3M, 2025-12-19 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes